119 studies found for:    gene expression analysis AND lymphoma
Show Display Options
Rank Status Study
1 Completed
Has Results
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: Rituximab;   Drug: Fludarabine phosphate;   Other: Leukemic or stroma cells
2 Active, not recruiting Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Peripheral T-cell Lymphoma
Interventions: Drug: prednisone;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: vincristine sulfate;   Drug: pralatrexate;   Other: laboratory biomarker analysis;   Genetic: comparative genomic hybridization;   Genetic: gene expression analysis;   Genetic: nucleic acid sequencing;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Genetic: microarray analysis;   Genetic: RNA analysis
3 Unknown  Biomarkers in Tissue Samples From Patients With Hodgkin Lymphoma Enrolled on ECOG-2496 Clinical Trial
Condition: Lymphoma
Interventions: Genetic: gene expression analysis;   Other: laboratory biomarker analysis
4 Unknown  Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab
Condition: Lymphoma
Interventions: Genetic: gene expression analysis;   Other: laboratory biomarker analysis
5 Terminated
Has Results
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: clofarabine;   Genetic: DNA methylation analysis;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: polymerase chain reaction;   Other: high performance liquid chromatography;   Other: laboratory biomarker analysis
6 Unknown  Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab
Condition: Lymphoma
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
7 Completed Analysis of Genes Present in Cutaneous T-Cell Lymphoma Cells
Condition: Lymphoma
Intervention: Other: laboratory biomarker analysis
8 Unknown  Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496
Condition: Lymphoma
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: polymorphism analysis;   Other: diagnostic laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Other: immunologic technique
9 Unknown  Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: cladribine;   Drug: temsirolimus;   Genetic: cytogenetic analysis;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis;   Other: liquid chromatography;   Other: mass spectrometry
10 Terminated Oblimersen Sodium and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Biological: oblimersen sodium;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Procedure: biopsy;   Genetic: microarray analysis;   Other: immunohistochemistry staining method;   Genetic: gene expression analysis;   Genetic: cytogenetic analysis
11 Active, not recruiting Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients
Condition: Lymphoma
Interventions: Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis
12 Unknown  Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Genetic: RNA analysis;   Genetic: gene expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
13 Unknown  GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Biological: sargramostim;   Genetic: gene expression analysis;   Genetic: gene rearrangement analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
14 Unknown  GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Biological: sargramostim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: gene expression analysis;   Genetic: gene rearrangement analysis;   Genetic: polymerase chain reaction;   Other: R-CHOP regimen;   Other: laboratory biomarker analysis
15 Unknown  DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402
Condition: Lymphoma
Interventions: Biological: rituximab;   Genetic: DNA analysis;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
16 Unknown  DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701
Condition: Lymphoma
Interventions: Biological: rituximab;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
17 Active, not recruiting Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Waldenström Macroglobulinemia
Interventions: Drug: vorinostat;   Biological: rituximab;   Drug: ifosfamide;   Drug: carboplatin;   Drug: etoposide;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Genetic: gene expression analysis
18 Terminated Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
Condition: Lymphoma
Interventions: Biological: rituximab;   Drug: bortezomib;   Drug: pegylated liposomal doxorubicin hydrochloride;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Genetic: proteomic profiling;   Other: flow cytometry;   Other: laboratory biomarker analysis
19 Recruiting Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
Conditions: Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Drug: bortezomib;   Biological: rituximab;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: DNA analysis;   Other: pharmacological study;   Other: pharmacogenomic studies
20 Unknown  Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Genetic: DNA analysis;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: medical chart review

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years